
|Videos|August 24, 2011
Dr. Ellis Discusses the Cell-Proliferation Marker Ki67
Author(s)Matthew J. Ellis, MD, PhD
Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67
Advertisement
Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses the cell-proliferation marker Ki67.
Ellis explains that the marker has been examined for many years because of its ability to show how many tumor cells are actively committed to cell division. An overexpression of Ki67 generally translates into a more aggressive clinical course. Despite this evidence there currently are not any guidelines or evidence to support testing for the marker in every tumor.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
3
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
4
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
5






































































